Affordable Access

Access to the full text

Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond

Authors
  • Costa, Ricardo L. B.1
  • Czerniecki, Brian J.1
  • 1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA , Tampa (United States)
Type
Published Article
Journal
npj Breast Cancer
Publisher
Nature Publishing Group UK
Publication Date
Mar 12, 2020
Volume
6
Issue
1
Identifiers
DOI: 10.1038/s41523-020-0153-3
Source
Springer Nature
License
Green

Abstract

Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2+ breast cancer. In this narrative review, we summarize advances in the understanding of immune system interactions, examine clinical developments, and suggest rationales for future investigation of immunotherapies for HER2+ breast cancer. Complex interactions have been found between different branches of the immune system, HER2+ breast cancer, and targeted treatments (approved and under investigation). A new wave of immunotherapies, such as novel HER2-directed mAbs, antibody drug conjugates, vaccines, and adoptive T-cell therapies, are being studied in a broad population of patients with HER2-expressing tumors. The development of immunotherapies for HER2+ breast cancer represents an evolving field that should take into account interactions between different components of the immune system.

Report this publication

Statistics

Seen <100 times